Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.48 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.44 |
| ▸ | ALPL | P05186 | 8/20 | 0.44 |
| ▸ | IDH1 | O75874 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.42 |
| ▸ | PRF1 | P14222 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7067036 | 0.91 | HSD17B1 (0.46) | SLC22A12GSPT1DDB1CRBNHSD17B1 | |
| SCHEMBL7058928 | 0.90 | SLC22A12 (0.49) | SLC22A12GSPT1DDB1CRBNHSD17B1 | |
| SCHEMBL6716694 | 0.86 | SLC22A12 (0.47) | SLC22A12GSPT1DDB1CRBNHSD17B1 | |
| SCHEMBL6716766 | 0.85 | FBP1 (0.44) | DDB1CRBNMAPK10 | |
| SCHEMBL6718361 | 0.84 | SLC22A12 (0.46) | SLC22A12GSPT1DDB1CRBNHSD17B1 | |
| SCHEMBL6718250 | 0.84 | ALPL (0.47) | SLC22A12GSPT1DDB1CRBNHSD17B1 | |
| SCHEMBL6720387 | 0.82 | PFKFB3 (0.52) | MAPK10MAPK9MAPK14 | |
| SCHEMBL6717790 | 0.81 | CDK1 (0.47) | IDH1MAPK10MAPK9MAPK14 | |
| SCHEMBL6715085 | 0.81 | SLC22A12 (0.48) | SLC22A12GSPT1DDB1CRBNALPL | |
| SCHEMBL6716714 | 0.81 | GSPT1 (0.45) | GSPT1DDB1CRBNMAPK10MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818651-B2 | ANTIINFLAMMATORY, ANTIASTHMATIC, SKIN, AND AUTOIMMUNE DISORDERS; CROHN*S DISEASE, ULCERATIVE COLITIS, CONJUCTIVITIS, MULTIPLE SCLEROSIS, AND RHEUMATOID ARTHRITIS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE | ALTANA PHARMA AG (DE) | 2004-11-16 | — | — | US | disclosed |
| US-20040044212-A1 | (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors | ALTANA PHARMA AG (DE) | 2004-03-04 | — | — | US | disclosed |
| EP-1337515-A1 | (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002040450-A1 | (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | ALTANA PHARMA AG (DE) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044212-A1 | (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors | PDE7B, PDE3B, PDE3A | SLC22A12 3059/4885GSPT1 1717/4885DDB1 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.